Information regarding Lung Cancer Treatment
Dear Birmingham Community Healthcare NHS Foundation Trust,
I would like to ask the following question regarding lung cancer treatment.
The purpose of these questions is to understand the variability of treatment within your trust and in context to the rest of the country.
Q1. In the past 3 months (or the latest 3 months data you have available), how many metastatic non-small cell lung cancer (NSCLC) patients were treated with any of the following:
• Afatinib
• Alectinib
• Atezolizumab monotherapy
• Atezolizumab in combination
• Bevacizumab
• Brigatinib
• Capmatenib
• Ceritinib
• Crizotinib
• Dacomitinib
• Dabrafenib with Trametinib
• Docetaxel monotherapy
• Durvalumab
• Erlotinib
• Gefitinib
• Gemcitabine
• Nintedanib with Docetaxel
• Nivolumab
• Osimertinib
• Paclitaxel
• Pembrolizumab monotherapy
• Pembrolizumab in combination
• Pemetrexed with Carboplatin/Cisplatin
• Tepotinib
• Vinorelbine with Cisplatin/Carboplatin
• Any other SACT
• Palliative care only
Thank you for taking the time to answer this question and I look forward to hearing from you.
Yours faithfully,
David Elder
Dear David
Birmingham Community HealthCare NHS Foundation Trust (the Trust) is in
receipt of your freedom of information request sent to us on 1 April 2022
about long cancer treatment.
The Trust will be dealing with it under the terms of the Freedom of
Information Act 2000 and will respond to you within 20 working days of
your request by 3 May 2022.
Please note the above, unique Request ID and quote this in all future
correspondence regarding this particular request.
Thank you.
Regards
Eugene C Aninweze
Freedom of Information Officer
Tel: 0121 466 7293
Internal: 67293
Email: [1][email address]
Web: [2]www.bhamcommunity.nhs.uk
Corporate Division
Legal Services Team
Birmingham Community Healthcare NHS Foundation Trust
3 Priestley Wharf, Holt Street, Birmingham Science Park, Aston
Birmingham B7 4BN
Dear David
Further to your freedom of information request, please find attached the
Trust’s response.
This request is now closed.
Thank you.
Regards
Eugene C Aninweze
Freedom of Information Officer
Tel: 0121 466 7293
Internal: 67293
Email: [1][email address]
Web: [2]www.bhamcommunity.nhs.uk
Corporate Division
Legal Services Team
Birmingham Community Healthcare NHS Foundation Trust
3 Priestley Wharf, Holt Street, Birmingham Science Park, Aston
Birmingham B7 4BN
From: BCHC, Foi (BIRMINGHAM COMMUNITY HEALTHCARE NHS FOUNDATION TRUST)
Sent: 04 April 2022 13:03
To: [FOI #850419 email]
Subject: Freedom of Information request - Information regarding Lung
Cancer Treatment [Request ID 2022-04-01(3)] - Acknowledgment
Dear David
Birmingham Community HealthCare NHS Foundation Trust (the Trust) is in
receipt of your freedom of information request sent to us on 1 April 2022
about long cancer treatment.
The Trust will be dealing with it under the terms of the Freedom of
Information Act 2000 and will respond to you within 20 working days of
your request by 3 May 2022.
Please note the above, unique Request ID and quote this in all future
correspondence regarding this particular request.
Thank you.
Regards
Eugene C Aninweze
Freedom of Information Officer
Tel: 0121 466 7293
Internal: 67293
Email: [3][email address]
Web: [4]www.bhamcommunity.nhs.uk
Corporate Division
Legal Services Team
Birmingham Community Healthcare NHS Foundation Trust
3 Priestley Wharf, Holt Street, Birmingham Science Park, Aston
Birmingham B7 4BN
We work to defend the right to FOI for everyone
Help us protect your right to hold public authorities to account. Donate and support our work.
Donate Now